{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:21:07Z","timestamp":1793852467075,"version":"4.6.1"},"reference-count":30,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,15]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The phase 3 TRANSFORM-1 study evaluated ruxolitinib (RUX) in combination with navitoclax (NAV) or placebo (PBO) in Janus kinase inhibitor\u2013na\u00efve adults with intermediate-2 or high-risk myelofibrosis and Eastern Cooperative Oncology Group performance status of \u22642. Patients were randomized 1:1 to NAV (200 mg\/d starting dose, or 100 mg escalated to 200 mg\/d) or PBO, with RUX dosed per label. The primary end point was \u226535% spleen volume reduction (SVR) at week 24 (SVR35W24). Secondary end points included change from baseline in total symptom score (TSS) at week 24 and SVR35 at any time. A total of 252 patients (NAV+RUX, n = 125; PBO+RUX, n = 127; median follow-up 20.3 months) were randomized; &amp;gt;80% had intermediate-2 risk, and \u223c50% had high-molecular risk disease. SVR35W24 was achieved by 63.2% with NAV+RUX vs 31.5% with PBO+RUX (P&amp;lt; .0001). Mean change in TSS at week 24 was not significantly different between NAV+RUX and PBO+RUX (\u221210.2 vs \u221211.6; P = .2852). SVR35 at any time was achieved in 76.8% with NAV+RUX vs 44.1% with PBO+RUX (nominal P&amp;lt; .0001). A \u226520% variant allele frequency reduction (exploratory end point) occurred in 58.5% (95% confidence interval [CI], 49.0-67.5) with NAV+RUX and 45.5% (95% CI, 36.4-54.8) with PBO+RUX. NAV+RUX showed higher hematologic toxicity vs PBO+RUX (grade 3\/4 thrombocytopenia, 54.0% vs 19.2%; grade 3\/4 neutropenia, 40.3% vs 8.8%); diarrhea (any grade, 41.9% vs 16.8%) was also more common. Cytopenias were generally manageable and reversible with dose adjustments. This trial was registered at www.clinicaltrials.gov as NCT04472598.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032360","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:13:49Z","timestamp":1782846829000},"page":"2029-2042","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"first","affiliation":[{"name":"1Department of Leukemia, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8522-1002","authenticated-orcid":false,"given":"Adam J.","family":"Mead","sequence":"additional","affiliation":[{"name":"2Medical Research Council Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, NIHR, Biomedical Research Centre, University of Oxford, Oxford, United Kingdom"},{"name":"3Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim C. P.","family":"Somervaille","sequence":"additional","affiliation":[{"name":"4Cancer Research UK Manchester Institute, The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[{"name":"5Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1011-8171","authenticated-orcid":false,"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Rheinisch-Westf\u00e4lische Technische Hochschule Aachen University, Aachen, Germany"},{"name":"7Center of Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Delage","sequence":"additional","affiliation":[{"name":"8Quebec CML-MPN Research Group, Montreal, Canada"},{"name":"9Integrated Cancer Center, CHU de Qu\u00e9bec, Laval University, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8121-438X","authenticated-orcid":false,"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[{"name":"10Universit\u00e9 Paris Cit\u00e9, Assistance Publique\u2013H\u00f4pitaux de Paris, H\u00f4pital Saint-Louis, Centre d\u2019Investigations Cliniques, INSERM, CIC1427, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Benton","sequence":"additional","affiliation":[{"name":"11Rocky Mountain Cancer Centers, US Oncology Network, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas K.","family":"Tantravahi","sequence":"additional","affiliation":[{"name":"12Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Lavi","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Rambam Health Care Campus, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Peng","family":"Yeh","sequence":"additional","affiliation":[{"name":"14China Medical University Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0505-5126","authenticated-orcid":false,"given":"Maria Teresa","family":"Gomez Casares","sequence":"additional","affiliation":[{"name":"15Hospital Universitario de Gran Canaria Dr. Negr\u00edn, Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8247-4901","authenticated-orcid":false,"given":"Emanuele","family":"Ammatuna","sequence":"additional","affiliation":[{"name":"16Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McDonald","sequence":"additional","affiliation":[{"name":"17Netcare Pretoria East Hospital, Pretoria, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-7459","authenticated-orcid":false,"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[{"name":"18Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[{"name":"19Department of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6881-417X","authenticated-orcid":false,"given":"Timothy","family":"Devos","sequence":"additional","affiliation":[{"name":"20Department of Hematology, University Hospitals Leuven, Leuven, Belgium"},{"name":"21Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-7093","authenticated-orcid":false,"given":"Andrew","family":"Perkins","sequence":"additional","affiliation":[{"name":"22Australian Centre for Blood Diseases, Monash University and The Alfred Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atanas","family":"Radinoff","sequence":"additional","affiliation":[{"name":"23Clinic of Hematology, St. Ivan Rilski University Multidisciplinary Hospital, Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9636-4113","authenticated-orcid":false,"given":"Omur Gokmen","family":"Sevindik","sequence":"additional","affiliation":[{"name":"24Department of Hematology, Istanbul Medipol University Faculty of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8288-7308","authenticated-orcid":false,"given":"Andrija","family":"Bogdanovic","sequence":"additional","affiliation":[{"name":"25Clinic of Hematology, University Clinical Center of Serbia, and Faculty of Medicine, University of Belgrade, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rastislav","family":"Moskal","sequence":"additional","affiliation":[{"name":"26AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason G.","family":"Harb","sequence":"additional","affiliation":[{"name":"26AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Murray","sequence":"additional","affiliation":[{"name":"26AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Jiang","sequence":"additional","affiliation":[{"name":"26AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6020-488X","authenticated-orcid":false,"given":"Avijeet S.","family":"Chopra","sequence":"additional","affiliation":[{"name":"26AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elektra J.","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"26AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalaja","family":"Potluri","sequence":"additional","affiliation":[{"name":"26AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-5289","authenticated-orcid":false,"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[{"name":"27Dipartimento di Oncologia ed Ematologia, Universit\u00e0 degli Studi di Milano, Policlinico di Milano, Ospedale Maggiore, Fondazione IRCCS Ca Granda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2026101511214180700_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"issue":"24","key":"2026101511214180700_bib2","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.2012.42.0240","article-title":"Improving survival trends in primary myelofibrosis: an international study","volume":"30","author":"Cervantes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2026101511214180700_bib3","doi-asserted-by":"crossref","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","article-title":"Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Vannucchi","year":"2015","journal-title":"Ann Oncol"},{"key":"2026101511214180700_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","article-title":"Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey","volume":"16","author":"Mesa","year":"2016","journal-title":"BMC Cancer"},{"issue":"16","key":"2026101511214180700_bib5","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.2022017423","article-title":"Myelofibrosis","volume":"141","author":"Passamonti","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2026101511214180700_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-018-0142-z","article-title":"Prefibrotic myelofibrosis: treatment algorithm 2018","volume":"8","author":"Finazzi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026101511214180700_bib7","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3390\/jcm10030436","article-title":"Acute myeloid leukemia evolving from myeloproliferative neoplasms: many sides of a challenging disease","volume":"10","author":"Mannelli","year":"2021","journal-title":"J Clin Med"},{"issue":"12","key":"2026101511214180700_bib8","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.clml.2017.08.002","article-title":"The treatment landscape of myelofibrosis before and after ruxolitinib approval","volume":"17","author":"Kuykendall","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"2026101511214180700_bib9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"2026101511214180700_bib10","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann Hematol"},{"issue":"9","key":"2026101511214180700_bib11","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"issue":"20","key":"2026101511214180700_bib12","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.3390\/cancers15205027","article-title":"A prognostic model to predict ruxolitinib discontinuation and death in patients with myelofibrosis","volume":"15","author":"Palandri","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2026101511214180700_bib13","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"issue":"15 suppl","key":"2026101511214180700_bib14","doi-asserted-by":"crossref","first-page":"e19539","DOI":"10.1200\/JCO.2020.38.15_suppl.e19539","article-title":"Real-world disease burden for patients (pts) with myelofibrosis (MF) treated with ruxolitinib (RUX)","volume":"38","author":"Gerds","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026101511214180700_bib15","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/ejh.70005","article-title":"Final results from a large, non-interventional, phase 4 study of ruxolitinib for the treatment of myelofibrosis in clinical routine","volume":"115","author":"Koschmieder","year":"2025","journal-title":"Eur J Haematol"},{"issue":"18","key":"2026101511214180700_bib16","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2217\/fon-2021-1358","article-title":"Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review","volume":"18","author":"Passamonti","year":"2022","journal-title":"Future Oncol"},{"issue":"13","key":"2026101511214180700_bib17","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/cncr.34205","article-title":"Defining disease modification in myelofibrosis in the era of targeted therapy","volume":"128","author":"Pemmaraju","year":"2022","journal-title":"Cancer"},{"issue":"8","key":"2026101511214180700_bib18","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","article-title":"Fedratinib in myelofibrosis","volume":"4","author":"Mullally","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2026101511214180700_bib19","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s40265-022-01718-y","article-title":"Pacritinib: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"issue":"18","key":"2026101511214180700_bib20","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s40265-023-01964-8","article-title":"Momelotinib: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"24","key":"2026101511214180700_bib21","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1182\/blood-2011-12-400929","article-title":"Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells","volume":"119","author":"M\u00e9rino","year":"2012","journal-title":"Blood"},{"issue":"18","key":"2026101511214180700_bib22","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1111\/jcmm.15730","article-title":"Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms","volume":"24","author":"Petiti","year":"2020","journal-title":"J Cell Mol Med"},{"issue":"4","key":"2026101511214180700_bib23","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","article-title":"Combined targeting of JAK2 and Bcl-2\/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors","volume":"5","author":"Waibel","year":"2013","journal-title":"Cell Rep"},{"issue":"3","key":"2026101511214180700_bib24","doi-asserted-by":"crossref","first-page":"e0114363","DOI":"10.1371\/journal.pone.0114363","article-title":"JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL","volume":"10","author":"Guo","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"2026101511214180700_bib25","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S2352-3026(22)00116-8","article-title":"Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study","volume":"9","author":"Pemmaraju","year":"2022","journal-title":"Lancet Haematol"},{"issue":"15","key":"2026101511214180700_bib26","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy","volume":"40","author":"Harrison","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026101511214180700_bib27","doi-asserted-by":"crossref","first-page":"100056","DOI":"10.1016\/j.bneo.2024.100056","article-title":"Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response","volume":"2","author":"Pemmaraju","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"11","key":"2026101511214180700_bib28","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1200\/JCO.21.02246","article-title":"Disease modification in myelofibrosis: an elusive Ggoal?","volume":"40","author":"Vachhani","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026101511214180700_bib29","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/blood-2022-157949","article-title":"The combination of navitoclax and ruxolitinib in JAK inhibitor-na\u00efve patients with myelofibrosis mediates responses suggestive of disease modification [abstract]","volume":"140","author":"Passamonti","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026101511214180700_bib30","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41591-025-03572-3","article-title":"Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial","volume":"31","author":"Rampal","year":"2025","journal-title":"Nat Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/16\/2029\/2594960\/blood_bld-2025-032360-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/16\/2029\/2594960\/blood_bld-2025-032360-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:21:49Z","timestamp":1792077709000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/16\/2029\/569436\/TRANSFORM-1-phase-3-study-efficacy-and-safety-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":30,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,10,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032360","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,15]]},"published":{"date-parts":[[2026,10,15]]}}}